What is the appropriate management of genital herpes simplex?

Management of Herpes Simplex Genital

For genital herpes management, initiate oral antiviral therapy immediately upon diagnosis, with treatment approach determined by whether this is a first episode, recurrent outbreak, or if suppressive therapy is warranted based on recurrence frequency.

First Clinical Episode

For patients presenting with their first episode of genital herpes, start antiviral therapy immediately to reduce symptom duration and severity 1. The available regimens include:

• Acyclovir 400 mg orally three times daily for 5 days
• Acyclovir 200 mg orally five times daily for 5 days
• Acyclovir 800 mg orally twice daily for 5 days
• Famciclovir 125 mg orally twice daily for 5 days
• Valacyclovir 500 mg orally twice daily for 5 days

The twice-daily or three-times-daily regimens should be prioritized over five-times-daily dosing to improve adherence 2. Continue treatment for 7-10 days for first episodes if lesions have not fully resolved by day 5 3.

Severe Disease Requiring Hospitalization

If the patient presents with disseminated infection, encephalitis, pneumonitis, hepatitis, or severe systemic illness requiring hospitalization, switch to intravenous therapy 1:

• Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution

Recurrent Episodes

Episodic Therapy

For patients with infrequent recurrences who prefer treatment only during outbreaks, provide a prescription so they can initiate therapy at the first sign of prodrome or lesion appearance 1. Treatment must begin within 1 day of symptom onset to be effective. Use the same regimens as listed above for first episodes, but for 5 days only.

Suppressive Therapy - The Preferred Approach

Suppressive therapy should be offered to all patients with symptomatic HSV-2 infection 2. This approach is particularly important because:

• It reduces recurrence frequency by ≥75% in patients with frequent outbreaks (≥6 per year) 1
• It decreases viral shedding and transmission risk to sexual partners 2
• It improves quality of life by preventing unpredictable outbreaks

Recommended suppressive regimens:

• Acyclovir 400 mg orally twice daily (preferred for long-term use, proven safe for up to 6 years) 1
• Famciclovir 250 mg orally twice daily
• Valacyclovir 500 mg orally once daily (less effective if ≥10 episodes/year)
• Valacyclovir 1000 mg orally once daily

Critical decision point: After 1 year of continuous suppressive therapy, reassess the patient to determine if continuation is needed, as recurrence frequency naturally decreases over time in many patients 1.

Special Populations

HIV-Infected or Immunocompromised Patients

These patients require higher doses and closer monitoring 1:

• Acyclovir 400 mg orally 3-5 times daily until clinical resolution
• For severe disease: IV acyclovir as above
• Caution: Valacyclovir at doses of 8 g/day has been associated with hemolytic uremic syndrome/thrombotic thrombocytopenic purpura in immunocompromised patients 1
• If lesions persist despite acyclovir therapy, suspect resistance and consider alternative agents (brincidofovir, imiquimod, topical cidofovir) 2

Pregnant Women

All childbearing-aged women with genital herpes must inform their obstetric providers about their HSV infection due to neonatal transmission risk 1. Routine screening of pregnant women is not recommended 2.

Essential Patient Counseling

Patient education is as critical as pharmacologic management 1:

• Explain the chronic, recurrent nature - this is a lifelong infection with no cure
• Abstain from sexual activity when lesions or prodromal symptoms are present
• Transmission occurs during asymptomatic periods - viral shedding happens even without visible lesions, especially in the first 12 months after infection and with HSV-2 (more than HSV-1)
• Condom use is essential during all sexual exposures with new or uninfected partners
• Partner notification is required - inform current and future sexual partners of their HSV status
• Suppressive therapy reduces but does not eliminate transmission risk 1

Diagnostic Considerations

For symptomatic patients: PCR from intact vesicles is the preferred diagnostic test 2, 4.

For serologic testing: HSV-2 serology should be obtained for 2:

• Patients with genital symptoms consistent with herpes but no virologic confirmation
• Persons told they have genital herpes without prior testing
• Sexual partners of known HSV-2 positive individuals
• Do NOT screen asymptomatic persons with low pretest probability 2

Common Pitfalls to Avoid

• Do not use topical acyclovir - it is substantially less effective than oral therapy and should be discouraged 3
• Do not delay treatment - episodic therapy only works if started within 1 day of symptom onset 1
• Do not assume HSV-1 genital infection requires different treatment - use the same regimens despite less comprehensive study data 2
• Do not continue famciclovir or valacyclovir suppression beyond 1 year without reassessment - insufficient long-term safety data existed at the time of the 1998 guidelines, though acyclovir is proven safe for 6 years 1

113312